$10.84
7.27% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Neumora Therapeutics Stock price

$10.84
-5.24 32.59% 1M
+1.17 12.10% 6M
-6.21 36.42% YTD
-1.17 9.74% 1Y
-6.16 36.24% 3Y
-6.16 36.24% 5Y
-6.16 36.24% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.85 7.27%
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Key metrics

Market capitalization $1.87b
Enterprise Value $1.53b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.85
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-250.64m
Free Cash Flow (TTM) Free Cash Flow $-184.08m
Cash position $342.52m
EPS (TTM) EPS $-1.85
P/E forward negative
Short interest 10.74%
Show more

Is Neumora Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Neumora Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

Buy
89%
Hold
11%

Financial data from Neumora Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.64 0.64
84% 84%
-
-0.64 -0.64
84% 84%
-
- Selling and Administrative Expenses 55 55
65% 65%
-
- Research and Development Expense 194 194
52% 52%
-
-250 -250
52% 52%
-
- Depreciation and Amortization 0.64 0.64
84% 84%
-
EBIT (Operating Income) EBIT -251 -251
48% 48%
-
Net Profit -294 -294
89% 89%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neumora Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neumora Therapeutics Stock News

Positive
Market Watch
2 days ago
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.
Neutral
Seeking Alpha
3 days ago
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – President and Chief Executive Officer Josh Pinto – Chief Financial Officer Rob Lenz – Head of Research and Development Conference Call Participants Julian Pino – Stifel Brian Abrahams – RBC Capital ...
Neutral
GlobeNewsWire
4 days ago
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
More Neumora Therapeutics News

Company Profile

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Head office United States
CEO Henry Gosebruch
Employees 124
Founded 2019
Website www.neumoratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today